0001209191-20-038189.txt : 20200622
0001209191-20-038189.hdr.sgml : 20200622
20200622162948
ACCESSION NUMBER: 0001209191-20-038189
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200618
FILED AS OF DATE: 20200622
DATE AS OF CHANGE: 20200622
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Wenqing Yao
CENTRAL INDEX KEY: 0001624033
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-12400
FILM NUMBER: 20979154
MAIL ADDRESS:
STREET 1: ROUTE 141 AND HENRY CLAY ROAD
CITY: WILMINGTON
STATE: DE
ZIP: 19880
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: INCYTE CORP
CENTRAL INDEX KEY: 0000879169
STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
IRS NUMBER: 943136539
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1801 AUGUSTINE CUT-OFF
CITY: WILMINGTON
STATE: DE
ZIP: 19803
BUSINESS PHONE: 3024986700
MAIL ADDRESS:
STREET 1: 1801 AUGUSTINE CUT-OFF
CITY: WILMINGTON
STATE: DE
ZIP: 19803
FORMER COMPANY:
FORMER CONFORMED NAME: INCYTE CORP
DATE OF NAME CHANGE: 20030318
FORMER COMPANY:
FORMER CONFORMED NAME: INCYTE GENOMICS INC
DATE OF NAME CHANGE: 20000710
FORMER COMPANY:
FORMER CONFORMED NAME: INCYTE PHARMACEUTICALS INC
DATE OF NAME CHANGE: 19930902
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-06-18
0
0000879169
INCYTE CORP
INCY
0001624033
Wenqing Yao
1801 AUGUSTINE CUT-OFF
WILMINGTON
DE
19803
0
1
0
0
EVP, Head of Discovery Chem
Common Stock
2020-06-18
4
A
0
25000
0.00
A
152188
D
Represents shares of common stock underlying performance shares earned upon the achievement of performance criteria determined to be satisfied on June 18, 2020. The performance shares will vest in full on June 28, 2022, subject to the Reporting Person's continued service with the Issuer through the vesting date. Each performance share initially represented the right to receive one share of common stock based on, and subject to, the approval of a new chemical entity developed by the issuer as a drug by the U.S. FDA or the European Medicines Agency during a specified performance period.
Includes an aggregate of 95,832 shares of common stock issuable pursuant to the performance shares reported above and previously reported restricted stock units and performance shares that have not vested as of June 18, 2020.
/s/ Wenqing Yao
2020-06-22